Valuation GlaxoSmithKline Pharmaceuticals Limited NSE India S.E.
Stocks
GLAXO
INE159A01016
Pharmaceuticals
|
Market Closed -
NSE India S.E.
07:05:07 2026-08-28 am EDT
|
5-day change | 1st Jan Change | ||
| 3,106.40 INR | +1.22% |
|
+7.04% | +25.58% |
| Aug. 03 | GSK India first-quarter profit rises on steady vaccine demand | RE |
| Aug. 03 | GlaxoSmithKline Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 | CI |
Company Valuation: GlaxoSmithKline Pharmaceuticals Limited
Data adjusted to current consolidation scope
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 281,714 | 224,319 | 329,173 | 487,432 | 386,822 | 526,192 | - |
| Change | - | -20.37% | 46.74% | 48.08% | -20.64% | 36.03% | - |
| Enterprise Value (EV) | 256,351 | 207,663 | 329,173 | 487,432 | 386,822 | 526,192 | 526,192 |
| Change | - | -18.99% | 58.51% | 48.08% | -20.64% | 36.03% | 0% |
| P/E | 16.6x | 36.7x | 55.8x | 52.5x | 37.3x | 45.3x | 39.4x |
| PBR | 10.6x | 12.9x | 18.5x | 25x | 17.1x | 19.9x | 16.7x |
| PEG | - | -0.6x | -16.49x | 0.9x | 3.2x | 3.8x | 2.6x |
| Capitalization / Revenue | 8.59x | 6.9x | 9.53x | 13x | 10.1x | 12.4x | 11.2x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 12.4x | 11.2x |
| EV / EBITDA | 0x | 0x | 0x | 0x | 0x | 35.6x | 30.9x |
| EV / EBIT | 0x | 0x | 0x | 0x | 0x | 36x | 30.9x |
| EV / FCF | 0x | 0x | 0x | 0x | 0x | 43.8x | 39.9x |
| FCF Yield | 2.75% | 1.96% | 1.67% | 2.6% | 2.19% | 2.28% | 2.5% |
| Dividend per Share 2 | 30 | 32 | 32 | 42 | 57 | 29.5 | 29.5 |
| Rate of return | 1.8% | 2.42% | 1.65% | 1.46% | 2.5% | 0.95% | 0.95% |
| EPS 2 | 100 | 36.05 | 34.83 | 54.76 | 61.15 | 68.52 | 78.88 |
| Distribution rate | 30% | 88.8% | 91.9% | 76.7% | 93.2% | 43% | 37.4% |
| Net sales 1 | 32,780 | 32,517 | 34,537 | 37,492 | 38,217 | 42,528 | 47,167 |
| EBITDA 1 | 8,273 | 8,043 | 9,087 | 11,774 | 13,092 | 14,794 | 17,020 |
| EBIT 1 | 7,592 | 7,385 | 8,390 | 11,106 | 12,428 | 14,621 | 17,016 |
| Net income 1 | 16,947 | 6,107 | 5,900 | 9,276 | 10,360 | 11,611 | 13,364 |
| Net Debt | -25,363 | -16,656 | - | - | - | - | - |
| Reference price 2 | 1,662.95 | 1,324.15 | 1,943.10 | 2,877.30 | 2,283.40 | 3,106.10 | 3,106.10 |
| Nbr of stocks (in thousands) | 169,406 | 169,406 | 169,406 | 169,406 | 169,406 | 169,406 | - |
| Announcement Date | 5/16/22 | 5/17/23 | 5/17/24 | 5/13/25 | 5/13/26 | - | - |
1INR in Million2INR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 33.44x | 12.14x | 24.6x | 0.59% | 1,047B | |
| 29.82x | - | - | 2% | 646B | |
| 32.61x | 7.57x | 15.74x | 2.68% | 451B | |
| 19.99x | 4.75x | 11.76x | 2.79% | 355B | |
| 21.76x | 5.62x | 13.93x | 2.85% | 291B | |
| 20.88x | 4.29x | 12.24x | 2.06% | 252B | |
| 27.35x | 7.07x | 12.56x | 2.33% | 234B | |
| 13.25x | 4.77x | 9.95x | 3.83% | 203B | |
| -44.51x | 6.43x | 25.11x | 2.26% | 181B | |
| Average | 17.17x | 6.58x | 15.74x | 2.38% | 406.59B | |
| Weighted average by Cap. | 24.24x | 8.07x | 17.81x | 1.97% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- GLAXO Stock
- GLAXO Stock
- Valuation GlaxoSmithKline Pharmaceuticals Limited
Select your edition
All financial news and data tailored to specific country editions
